STRATA Skin Sciences Inc (NASDAQ:SSKN), which happens to be a top end medical technology company focusing majorly in the development, commercialization as well as the marketing of innovative products for facing out of a wide range of dermatologic conditions has moved ahead to make an important announcement.
STRATA was happy to officially launch the Nordlys device at the American Society for Lasers in Medicine and Surgery (ASLMS), an activity that happened in San Diego from April 5-9, 2017.Asides from this announcement, it also moved ahead to make public the most awaited news by a number of the concerned parties. It looks forward to obtain high revenues and earnings as well from the sale of Nordlys products for the 2017 balance.
The Chief Executive Officer of STRATA, Frank McCaney, in addressing a press conference said, “We are thrilled to launch the latest in non-ablative fractionated laser technology with the Nordlys device. Ellipse and STRATA have been working closely with globally renowned dermatologist Dr. Vic Ross to create the most advanced rejuvenation laser on the market. In a podium presentation at ASLMS, Dr. Ross demonstrated the uses and advantages of the Nordlys device, and presented the results of his study utilizing the Nordlys novel FRAX 1550 rolling fractional 1550nm laser on improving the effects of aging on facial skin.”
The various dermatologists around the globe have in the recent past been making consultations with the company in regards to the way they provider would help them give a lift to their provision of services.
This company in a number of board meetings delved in the matter, and according to one of the company’s top officials, it would be a prudent move for the provider to redirect more funds into enhancing its products and services as well.
The top executive proceeded, “We expect that the system can become the device of choice for dermatologists and other physicians practicing in the aesthetic medicine field. We are forecasting sales of the device and accessories to be in the range of $4.0 to $4.5 million for 2017 which would contribute $500,000-600,000 in non-GAAP adjusted EBITDA.”
The company promise a lot of good things to happen in future, but all we have to do is just wait and see!
